Alnylam Pharmaceuticals, Inc.
DE ˙ XTRA ˙ US02043Q1076
251,80 € ↑6,70 (2,73%)
2026-06-03
DEL PRIS
SecurityDE:DUL / Alnylam Pharmaceuticals, Inc.
InstitutionAlliancebernstein L.p.
Latest Disclosed Ownership44,641 shares
Latest Disclosed Value $ 17,751,494
Alliancebernstein L.p. reports 0.73% increase in ownership of DUL / Alnylam Pharmaceuticals, Inc.

On May 15, 2026 - Alliancebernstein L.p. filed a 13F-HR form disclosing ownership of 44,641 shares of Alnylam Pharmaceuticals, Inc. (DE:DUL) valued at $12,753,934 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 44,319 shares of Alnylam Pharmaceuticals, Inc.. This represents a change in shares of 0.73% during the quarter. The current value of the position is $11,240,604 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,641 322 0.73 17,751 0.73 0.0048
2026-02-17 2025-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,319 543 1.24 17,623 -11.71 0.0056
2025-11-14 2025-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,776 -23,355 -34.79 19,962 -8.81 0.0063
2025-08-14 2025-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 67,131 22,294 49.72 21,891 80.82 0.0071
2025-05-15 2025-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,837 247 0.55 12,107 15.38 0.0044
2025-02-12 2024-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 44,590 -8,034 -15.27 10,492 -27.51 0.0036
2024-11-14 2024-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 52,624 7,251 15.98 14,473 31.27 0.0049
2024-08-14 2024-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,373 -8,803 -16.25 11,026 36.18 0.0038
2024-05-14 2024-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 54,176 -466,663 -89.60 8,097 -91.88 0.0029
2024-02-14 2023-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 520,839 -19,867 -3.67 99,694 4.11 0.0384
2023-11-14 2023-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 540,706 -9,573 -1.74 95,759 -8.38 0.0407
2023-08-15 2023-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 550,279 14,320 2.67 104,520 -2.65 0.0427
2023-05-15 2023-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 535,959 464,775 652.92 107,363 534.68 0.0460
2023-02-15 2022-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 71,184 -3,784 -5.05 16,917 12.73 0.0076
2022-11-15 2022-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 74,968 -600,039 -88.89 15,006 -84.76 0.0073
2022-08-15 2022-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 675,007 618,470 1,093.92 98,450 966.40 0.0450
2022-05-13 2022-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 56,537 -13,343 -19.09 9,232 -22.09 0.0036
2022-02-14 2021-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 69,880 3,194 4.79 11,850 -5.89 0.0042
2021-11-10 2021-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 66,686 4,765 7.70 12,591 19.95 0.0050
2021-07-30 2021-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 61,921 -5,798 -8.56 10,497 9.79 0.0042
2021-05-06 2021-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 67,719 -55,758 -45.16 9,561 -40.42 0.0042
2021-02-08 2020-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 123,477 56,687 84.87 16,048 65.02 0.0076
2020-11-12 2020-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 66,790 -10,901 -14.03 9,725 -15.49 0.0052
2020-08-13 2020-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 77,691 4,490 6.13 11,507 44.42 0.0068
2020-05-14 2020-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 73,201 -54,587 -42.72 7,968 -45.86 0.0057
2020-02-18 2019-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 127,788 12,645 10.98 14,717 58.93 0.0084
2019-11-14 2019-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 115,143 11,272 10.85 9,260 22.86 0.0058
2019-08-14 2019-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 103,871 55,080 112.89 7,537 65.29 0.0047
2019-05-14 2019-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,791 -199 -0.41 4,560 27.66 0.0030
2019-02-13 2018-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,990 -698 -1.40 3,572 -17.87 0.0027
2018-11-08 2018-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 49,688 -1,640 -3.20 4,349 -13.97 0.0028
2018-08-13 2018-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,328 2,045 4.15 5,055 -13.88 0.0035
2018-05-14 2018-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 49,283 3,830 8.43 5,870 1.65 0.0042
2018-02-13 2017-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,453 1,680 3.84 5,775 12.29 0.0041
2017-11-13 2017-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 43,773 -4,100 -8.56 5,143 34.70 0.0039
2017-08-10 2017-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,873 398 0.84 3,818 56.93 0.0030
2017-05-11 2017-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,475 -330 -0.69 2,433 35.92 0.0019
2017-02-13 2016-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 47,805 -2,259 -4.51 1,790 -47.24 0.0015
2016-11-10 2016-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 50,064 -150 -0.30 3,393 21.79 0.0029
2016-08-11 2016-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 50,214 600 1.21 2,786 -10.53 0.0024
2016-05-13 2016-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 49,614 -325 -0.65 3,114 -33.76 0.0026
2016-02-16 2015-12-31 13F/A-1 ALNYLAM PHARMACEUTICALS COM 02043Q107 49,939 -1,185 -2.32 4,701 14.44 0.0040
2016-02-12 2015-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 49,939 4,013
2015-11-13 2015-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,124 -861 -1.66 4,108 -34.07 0.0035
2015-08-14 2015-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 51,985 3,477 7.17 6,231 23.02 0.0051
2015-05-13 2015-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 48,508 2,970 6.52 5,065 14.67 0.0041
2015-02-13 2014-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 45,538 3,900 9.37 4,417 35.82 0.0037
2014-11-13 2014-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,638 500 1.22 3,252 25.13 0.0027
2014-08-13 2014-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 41,138 -74,812 -64.52 2,599 -66.62 0.0022
2014-05-13 2014-03-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 115,950 -5,426 -4.47 7,785 -0.29 0.0067
2014-02-13 2013-12-31 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 121,376 -1,972 -1.60 7,808 -1.11 0.0070
2013-11-14 2013-09-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 123,348 158 0.13 7,896 106.70 0.0078
2013-08-13 2013-06-30 13F ALNYLAM PHARMACEUTICALS COM 02043Q107 123,190 123,190 3,820 0.0041
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.